CD274 and neoplasm: In non-small cell lung cancer (NSCLC), driver mutations, the expression levels of programmed cell death ligand 1 (PD-L1), and tumor mutational burden (TMB) have been identified as practical biomarkers for predicting the effectiveness of immunotherapy 16-22, however, widely acknowledged biomarkers in SCLC immunotherapy are still absent.